Lipocine (LPCN) Earning Somewhat Positive Press Coverage, Report Shows

Media stories about Lipocine (NASDAQ:LPCN) have trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Lipocine earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 46.5002463158813 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the news headlines that may have effected Accern’s analysis:

A number of research firms recently issued reports on LPCN. Roth Capital set a $38.00 target price on Lipocine and gave the stock a “buy” rating in a research note on Thursday, August 10th. ValuEngine cut Lipocine from a “hold” rating to a “sell” rating in a research note on Thursday, August 10th. Finally, Canaccord Genuity set a $11.00 target price on Lipocine and gave the stock a “buy” rating in a research note on Monday, August 7th.

Lipocine (LPCN) traded down $0.18 during midday trading on Tuesday, reaching $3.69. The company had a trading volume of 130,400 shares, compared to its average volume of 240,745. Lipocine has a twelve month low of $3.13 and a twelve month high of $5.33.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at

Lipocine Company Profile

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Insider Buying and Selling by Quarter for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply